

Potentially Inappropriate Medications in Older Adults According to Beers List and STOPP Criteria

Note: These guidelines are not applicable in all circumstances. Avoid use when possible. Use with caution when necessary.

CENTRAL NERVOUS SYSTEM

Beers List

<u>Anticholinergic Antidepressants (alone or in combination):</u> Amitriptyline, amoxapine, clomipramine, desipramine, doxepin (> 6 mg/d) imipramine, nortriptyline, paroxetine, protriptyline, trimipramine

<u>Antipsychotics – 1st (conventional) & 2nd (atypical) generation</u>: Avoid except in schizophrenia, bipolar or short-term use as antiemetic during chemotherapy.

Increase risk of CVA, increase rate of cognitive decline and mortality in people with dementia.

Barbiturates:

Amobarbital, butabarbital, butalbital, mephobarbital, pentobarbital, phenobarbital, secobarbital

Benzodiazepines (BZDs):

Short- and intermediate-acting: alprazolam, estazolam, lorazepam, oxazepam, temazepam, triazolam

Long-acting BZDs: clorazepate, chlordiazepoxide (alone or in combination with amitriptyline or clidinium), clonazepam, diazepam, flurazepam, quazepam

<u>Non-BZD "Z" Drugs</u>: Eszopiclone, zaleplon, zolpidem

<u>Others</u>: Meprobamate, ergoloid, mesylates, isoxsuprine

STOPP Criteria

Tricyclic antidepressants:

- In patients with dementia
- First line for depression

<u>SSRIs with</u> \sqrt{Na}

Neuroleptics:

- With anticholinergic s/e
- For behavior in dementia
- Used as hypnotics

<u>Antipsychotics in Parkinsonism or Lewy Body disease:</u> (except quetiapine and clozapine)

Benzodiazepines: Used > 4 weeks

Anticholinergic/Antimuscarinics:

- In dementia or delirium
- Used to treat EPS of neuroleptic medications

Phenothiazines:

As first-line treatment

Levodopa or Dopamine: Agonists used for benign essential tremor

CARDIOVASCULAR

Beers List

<u>Peripheral Alpha-1 Blockers</u>: Doxazosin, Prazosin, Terazosin

Central Alpha Agonists:

Clonidine for first-line treatment of hypertension (HTN) Other CNS alpha-agonists:

- Guanabenz
- Methyldopa
- Guanfacine
- Reserpine (> 0.1 mg/d)

Others:

Disopyramide Dronedarone, amiodarone

Digoxin (for first-line treatment of atrial fibrillation or of heart failure)

Nifedipine (immediate release form)

Acetylcholinerase inhibiters

Tertiary tricyclic antipsychotics

- Antipsychotics:
 - Chlorpromazine
 - Thioridazine
 - Olanzapine

Trimethoprim-sulfamethoxazole (with ACE inhibitor or ARB and decreased creatinine clearance)

In patients with heart failure:

NSAIDs, COX-2 inhibitors, non-dihydropyridine calcium channel blockers, thiazolidinediones, cilostazol, dronederone

STOPP Criteria

Centrally acting anti-hypertensives:

- Methyldopa
- Clonidine
- Guanfacine

Loop diuretic for:

- HTN first-line
- Dependent ankle edema
- HTN with urinary incontinence

Others:

- Digoxin for heart failure
- Diltiazem and Verapamil in New York Heart Association (NYHA) class 3-4 heart failure
- Beta blockers when heart rate less than 50 beats/min
- Amiodarone first-line for supraventricular tachycardia (SVT)



ENDOCRINE

Beers List

Androgens:

- Methyltestosterone
- Testosterone

Desiccated thyroid:

 Estrogens with or without progestines (oral or transdermal – excludes intravaginal estrogen)

Growth hormone

Sliding scale insulin:

 Insulin regimens containing only short- or rapid-acting insulin dosed according to current blood glucose levels without concurrent use of basal or long-acting insulin

Long-acting Sulfonylureas:

- Chlorpropamide
- Glimepiride
- Glyburide (aka glibenclamide)

STOPP Criteria

- Sulfonylureas with prolonged duration of action in type 2 diabetes mellitus:
 - Chlorpropamide
 - Glimepiride
- Thiazolidenediones in persons with heart failure
 - Rosiglitazone
- Pioglitazone
- Beta blockers in persons with diabetes mellitus with frequent hypoglycemic episodes
- Estrogens in people with history of breast cancer or venous thromboembolism
- Estrogens without progesterone in women with an intact uterus
- Androgens in the absence of primary or secondary hypogonadism

ANALGESICS

Beers List

Non-cyclooxygenase-2 (Non-COX-2) NSAIDs:

Aspiring > 325 mg/day, diclofenac, diflunisal, etodolac, fenoprofen, ibuprofen, ketoprofen, meclofenomate, mefenamic acid, meloxicam, nabumetone naproxen, oxaprozin, piroxicam, sulindac, tolmetin, indomethacin, ketorolac (includes parenteral)

Other:

Meperidine

STOPP Criteria

- Use of oral or transdermal "strong" opioids as first-line therapy for mild pain:
 - Morphine
 - Oxycodone
 - Fentanyl
 - Buprenorphine
 - Methadone
 - Tramadol
- Use of regular, scheduled opioids without a scheduled laxative
- Use of long-acting opioids without short-acting opioids for breakthrough pain

DRUGS THAT INCREASE RISK OF FALLS

Beers List

Anticonvulsants

Antipsychotics

Benzodiazepines

Tricyclic antidepressants (TCAs)

Serotonin reuptake inhibitors (SSRIs)

Serotonin norepinephrine reuptake inhibitors (SNRIs)

Opioids

Non-benzodiazepine, benzodiazepine receptor agonists (Non-BZD "Z" drugs):

Eszopiclone

- Zaleplon
- Zolpidem

STOPP Criteria

Benzodiazepines (BZDs)

Neuroleptic drugs

Vasodilator drugs with persistent postural hypotension:

- Alpha-1 receptor blockers
- Calcium channel blockers
- Nitrates (long-acting)
- ACE inhibitors
- ARBs
- Minoxidil
- Hydralazine

<u>Hypnotic Non-benzodiazepine, benzodiazepine receptor agonists</u> (Non-BZD "Z" drugs):

Eszopiclone

- Zaleplon
- Zolpidem

MUSCULOSKELETAL

Beers List

Carisoprodol, cyclobenzaprine, chlorzoxazone, metaxalone, methocarbamol, orphenadrine

STOPP Criteria

- Non-COX-2 selective NSAIDs without concurrent proton pump inhibitor (PPI) or H2 antagonist in persons with history of peptic ulcer disease or gastrointestinal bleeding
- NSAID with established hypertension or heart failure
- Long-term use of NSAIDs (> 3 months) for relief of osteoarthritis symptom pain where paracetamol has not been tried (use simple analgesics first)
- Long-term corticosteroid use (> 3 months) as monotherapy for rheumatoid arthritis
- Oral corticosteroid use for osteoarthritis
- Long-term NSAID or colchicine use for prevention of gout relapse (use xanthine-oxidase inhibitors first-line if not contraindicated)
- COX-2 NSAIDs in concurrent cardiovascular disease
- NSAID with corticosteroids without PPI
- Oral bisphosphonates in persons with history of upper gastrointestinal disease



ANTICHOLINERGICS

Beers List

First Generation Antihistamines:

Brompheniramine, carbinoxamine, chlorpheniramine, clemastine, cyproheptadine, dexbrompheniramine, dexchlorpheniramine, dimenhydrinate, diphenhydramine (oral), doxylamine, hydroxyzine, meclizine, promethazine, pyrilamine, triprolidine

Antiparkinsonian Agents:

Benztropine, trihexyphenidyl

Antispasmodics:

Atropine (excludes ophthalmic), belladonna alkaloids, clindiniumchlordizepoxide, dicyclomine, homatopine (excludes ophthalmic), hyoscyamine, methscopolamine, propantheline, scopolamine

Antidepressants:

Amitriptyline, amoxapine, clomipramine, desipramine, doxepin (> 6mg), imipramine, nortriptyline, paroxetine, protriptyline, trimipramine

Antimuscarinics:

Darifenacin, fesoterodine, flavoxate, oxybutinin, solifenacin, tolterodine, trospium

Antipsychotics:

Chlorpromazine, clozapine, loxapine, olanzapine, perphenazine, thioridazine, trifluoperazine

<u>Skeletal muscle relaxants</u>: Cyclobenzaprine, orphenadrine

Antiarrhythmic:

Disopyramide

Antiemetics:

Metoclopramide, prochloroperazine, promethazine

STOPP Criteria

- Concomitant use of two or more drugs with antimuscarinic/ anticholinergic properties – examples:
 - Bladder antispasmodics
 - Intestinal antispasmodics
 - Tricyclic antidepressants
 - First generation antihistamines

ANTITHROMBOTIC

Beers List (Avoid)

Dipyridamole – oral, short-acting (does not apply to the extendedrelease combination with aspirin) Warfarin used with amiodarone Warfarin used with NSAIDs Warfarin used with ciprofloxacin Warfarin used with macrolides (excluding azithromycin) Warfarin used with trimethoprim-sulfamethoxazole

Beers List (Use With Caution)

Aspirin for primary prevention of cardiac disease and colorectal cancer Dabigatran Prasugrel Rivaroxaban

STOPP Criteria

Aspirin, clopidogrel, dipyridamole, vitamin K antagonist, direct thrombin inhibitor, factor Xa inhibitors in patients with a high risk for bleeding

GASTROINTESTINAL AND GENITORURINARY

Beers List – Gastrointestinal

Aspirin (> 325 mg) Non-COX-2 selective NSAIDS Metoclopramide (unless for gastroparesis with duration of use not to exceed 12 weeks except in rare cases) Mineral oil, administered orally PPIs (avoid scheduled use > 8 weeks unless person at high risk)

STOPP Criteria – Gastrointestinal

- Prochlorperazine or metoclopramide with Parkinsonian symptoms
- PPIs for uncomplicated peptic ulcer disease or erosive peptic esophagitis at full therapeutic dosage for > 8 weeks
- Drugs likely to cause constipation in persons with chronic constipation where non-constipating alternatives are appropriate
 Antimus carinic (antichaling rais drugs)
 - Antimuscarinic/anticholinergic drugs
 - Opioids
 - Verapamil
 - Aluminum antacids
- Oral elemental iron doses greater than 200 mg/day examples:
 - Ferrous fumarate
 - Ferrous gluconate
 - Ferrous sulfate
 - Polysaccharide-iron complex (PIC)
 - PIC plus folic acid
 Vitamin B12
 - VILAIIIIII DIZ

Beers List – Genitourinary

Desmopressin for nocturia or nocturnal polyuria

STOPP Criteria – Genitourinary

- Selective alpha-1 blockers in persons with symptomatic orthostatic hypotension or micturition syncope
- Antimuscarinic drugs for overactive bladder in persons with:
 - Dementia or chronic cognitive impairment
 - Narrow-angle glaucoma
 - Chronic prostatism

Aspirin:

- > 160 mg daily long-term use
- With history of peptic ulcer disease without concomitant PPI
- Plus clopidogrel as secondary stroke prevention

Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors:

- With antiplatelet agents in patients with stable coronary, cerebrovascular or peripheral arterial disease without a clear indication for anticoagulant therapy
- In combination with aspirin in patients with chronic atrial fibrillation
- For > 6 months for first deep venous thrombosis (DVT) or > 12 months for first pulmonary embolus without continuing risk factors

Ticlopidine in any circumstance

NSAIDs:

- In combination with vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors
- In combination with antiplatelets without PPI prophylaxis



RENAL

Beers List

NSAIDs (non-COX and COX- selective, oral and parenteral, nonacetylated salicylates) in chronic kidney disease (CKD) stage IV or creatinine clearance < 30 ml/min

Reduce dose if CrCl:

Dofetilide 20-59 ml/min Edoxaban 15-50 ml/min Enoxaparin < 30 ml/min Rivaroxaban 15-50 ml/min for nonvalvular atrial fibrillation Gabapentin < 60 ml/min Levetiracetam < 80 ml/min Pregabalin < 60 ml/min Tramadol immediate release < 30 ml/min Cimetidine < 50 ml/min Famotidine < 50 ml/min Nizatidine < 50 ml/min Ranitidine < 50 ml/min Colchicine < 30 ml/min

Avoid use if CrCl:

Amiloride < 30 ml/min Apixaban < 25 ml/min Dabigatran < 30 ml/min Dofetilide < 20 ml/min Edoxaban < 15 or > 95 ml/min Fondaparinux < 30 ml/min Rivaroxaban < 30 ml/min Spironolactone < 30 ml/min Triamterene < 30 ml/min Duloxetine < 30 ml/min Tramadol extended-release form Probenecid < 30 ml/min Nitrofurantoin < 30 ml/min Ciprofloxacin < 30 ml/min Trimethoprim-Sulfamethoxazole < 30 ml/min

STOPP Criteria

Avoid use if eGFR: Digoxin < 30 ml/min/1.73 m² Direct thrombin inhibitors < 30 ml/min/1.73 m² Factor Xa inhibitors < 15 ml/min/1.73 m² NSAIDs < 50 ml/min/1.73 m² Colchicine < 10 ml/min/1.73 m² Metformin < 30 ml/min/1.73 m²

MISCELLANEOUS

Beers List

Drugs that exacerbate or cause SIADH or hyponatremia: Antipsychotics¹, carbamazepine, diuretics, mirtazapine, SNRIs, SSRIs, TCAs, tramadol

Drugs that can induce or worsen delirium:

Anticholinergics

Antipsychotics¹

Benzodiazepines

Corticosteroids (oral or parenteral²)

- H2-receptor antagonists:
 - Cimetidine
 - Famotidine
 - Nizatidne
 - Ranitidine

Meperidine

Non-benzodiazepine, benzodiazepine receptor agonist hypnotics (non-BZD "Z" drugs):

- Eszopiclone
- Zaleplon
- Zolpidem

Drugs that worsen dementia or cognitive impairment:

Anticholinergics

Antipsychotics¹, chronic and as-needed use

Non-benzodiazepine, benzodiazepine receptor agonist hypnotics (non-BZD "Z" drugs):

- Eszopiclone
- Zaleplon
- Zolpidem

Dextromethorphan/quinidine (does not apply to Pseudobulbar Affect)

Drugs that worsen Parkinson's Disease:

Antiemetics:

- Metoclopramide
- Prochlorperazine
- Promethazine

All antipsychotics (except clozapine, pimavanserin, quetiapine - none of these are ideal in efficacy or safety)

STOPP Criteria

Respiratory:

- Theophylline as monotherapy for COPD
- Systemic corticosteroids instead of inhaled corticosteroids for maintenance therapy in moderate-severe COPD
- Anti-muscarinic bronchodilators with history of glaucoma or bladder outlet obstruction
- Benzodiazepines with acute or chronic respiratory failure



Quality Improvement Organizations Sharing Knowledge. Improving Health Care. CENTERS FOR MEDICARE & MEDICAID SERVICES

Quality Innovation Network

WWW.TMFNETWORKS.ORG

Sources: American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults, Journal of the American Geriatrics Society 63:2227-2246, 2015; STOPP/START Criteria for Potentially Inappropriate Prescribing in Older People version 2; Mahoney, Denis et.al. Age and Ageing, volume 44, Issue 2, 1 March 2015, pages 213-218, supplemental data pages 1-23.

¹May be required to treat concurrent schizophrenia, bipolar disorder and other selected mental health conditions, but should be prescribed in the lowest effective dose and shortest possible duration.

²Oral and parenteral corticosteroids may be required for conditions such as exacerbation of COPD, but should be prescribed in the lowest effective dose and for the shortest possible duration.

This material was originally prepared by Healthcare Quality Strategies, Inc., Delmarva Foundation – Maryland, and Delmarva Foundation – District of Columbia, and modified by TMF Health Quality Institute, the Medicare Quality Innovation Network Quality Improvement Organization, under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services. The contents do not necessarily reflect CMS policy. 11SOW-QINQIO-C3.6-18-16 Published 8/2018; Revised 05/2020